Bio-Path Holdings (BPTH) Reports Q3 Loss of $0.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Bio-Path Holdings Reports Third Quarter 2015 Operational and Financial Results
November 10, 2015 8:55 AM ESTHOUSTON--(BUSINESS WIRE)-- Bio-Path Holdings, Inc., (NASDAQ: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced operational and financial results for the quarter ended September 30, 2015.
The third quarter of 2015 proved to be an exciting time for Bio-Path, as we made significant progress with our lead product candidate, BP1001, said Peter Nielsen, President and Chief Executive Officer of Bio-Path. We reported that one patient with advanced acute myeloid leukemia in our Phase Ib trial achieved complete remission, and another patient... More
